Another Teva exec joins Hikma in newly-created position

Jordan-based drugmaker Hikma Pharmaceuticals (LSE: HIK) has appointed Henriette Nielsen to the newly-created role of chief transformation officer.

In this role, Ms Nielsen will be responsible for leading a number of initiatives across Hikma’s global operations to improve operational efficiency and ensure that Hikma achieves its strategic objectives. She will join Hikma’s executive committee and will report directly to Siggi Olafsson, London-listed  Hikma’s chief executive.  Her appointment is effective from today (June 4, 2018).

Ms Nielsen joins Hikma from US subsidiary of Israel’s Teva Pharmaceutical Industries (NYSE: TEVA), where she was most recently senior vice president, chief transformation officer, global marketing and portfolio. Her previous experience includes founder of System Matters, a healthcare and impact investing consultancy, and general counsel and EVP at Actavis Group. She also held senior roles at Alpharma, Netdoktor and Kromann Reumert.